RESEARCH TRIANGLE PARK, NC--(Marketwire - July 3, 2008) - The oncology market will grow
from $57 billion in 2007 to more than $85 billion in 2013, according to a
new report by Cutting Edge Information.
Along the way, many drugs are expected to be big winners for their
companies: a total of 21 oncology and adjunct drugs are anticipated to
reach blockbuster status by 2012.
The new study, "The Oncology Market Forecast to 2013," provides a detailed
look at the entire oncology market -- including drug class breakdowns,
profiles of top companies, and current and future blockbusters. A report
brochure is available for download here:
http://www.cuttingedgeinfo.com/oncology/TA220_Download.asp
"The cancer market is projected to increase dramatically, and companies
across the industry are scrambling to increase their share in this market,"
said Eric Bolesh, Research Team Leader at Cutting Edge Information.
In some cases, firms are seeking to replace oncology sales that will be
lost to patent expirations in 2010 or 2011. In other cases, they're hoping
a healthy oncology portfolio will replace sales lost in other therapeutic
areas.
"In both of these situations," Bolesh said, "newcomers face tremendous
competition from established players. Much oncology market share is
heavily concentrated in only a few companies."
The 420+ page report examines more than 130 drugs and provides market
analysis on multiple levels, including:
Individual Drug Profiles - Drug profiles include information about drugs'
competitive, strategic and market growth positions based on the following
information:
-- Past financial performance and future prospects
-- Patent/litigation information
-- Development progress across all indications
-- Market-changing events, including competitor patent expirations and
trial results
Oncology Indication Market Outlook - Detailed outlooks for the breast,
colorectal, lung and prostate cancer and leukemia markets. This outlook is
based on the following included information:
-- Epidemiology
-- Drug sales & forecasts
-- Pipeline summaries
-- Market events
-- Marketed products
Company Profiles - Oncology breakdowns for 14 pharmaceutical and
biotechnology companies. These firms either have established oncology
franchises or exciting development pipelines for new cancer compounds.
Research includes:
-- Market share and oncology revenue
-- Competitive and strategic positioning in the oncology market
-- Company performance -- strengths, weaknesses and competitive threats
-- Drug-by-drug examination of company's oncology pipeline
Contact Information: CONTACT INFORMATION:
Eric Bolesh
919-433-0209